KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Nektar Therapeutics (NKTR) over the last 15 years, with Q3 2025 value amounting to 0.52%.

  • Nektar Therapeutics' Return on Capital Employed rose 700.0% to 0.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.52%, marking a year-over-year increase of 700.0%. This contributed to the annual value of 0.36% for FY2024, which is 1600.0% up from last year.
  • Nektar Therapeutics' Return on Capital Employed amounted to 0.52% in Q3 2025, which was up 700.0% from 0.63% recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Return on Capital Employed ranged from a high of 0.29% in Q1 2021 and a low of 0.71% during Q4 2023
  • Its 5-year average for Return on Capital Employed is 0.53%, with a median of 0.55% in 2025.
  • In the last 5 years, Nektar Therapeutics' Return on Capital Employed crashed by -2500bps in 2022 and then skyrocketed by 2800bps in 2024.
  • Over the past 5 years, Nektar Therapeutics' Return on Capital Employed (Quarter) stood at 0.4% in 2021, then tumbled by -38bps to 0.56% in 2022, then fell by -29bps to 0.71% in 2023, then skyrocketed by 40bps to 0.43% in 2024, then dropped by -21bps to 0.52% in 2025.
  • Its last three reported values are 0.52% in Q3 2025, 0.63% for Q2 2025, and 0.55% during Q1 2025.